GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » Revenue

Lee's Pharmaceutical Holdings (HKSE:00950) Revenue : HK$1,400 Mil (TTM As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Lee's Pharmaceutical Holdings Revenue?

Lee's Pharmaceutical Holdings's revenue for the six months ended in Jun. 2024 was HK$658 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$1,400 Mil. Lee's Pharmaceutical Holdings's Revenue per Share for the six months ended in Jun. 2024 was HK$1.12. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$2.38.

Warning Sign:

Lee's Pharmaceutical Holdings Ltd revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Lee's Pharmaceutical Holdings was 9.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -4.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -0.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Lee's Pharmaceutical Holdings's highest 3-Year average Revenue per Share Growth Rate was 46.80% per year. The lowest was -4.70% per year. And the median was 22.90% per year.


Lee's Pharmaceutical Holdings Revenue Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Revenue Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,216.72 1,266.16 1,233.15 1,053.03 1,399.97

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 583.98 512.31 540.73 658.35 741.62

Competitive Comparison of Lee's Pharmaceutical Holdings's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Revenue distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Revenue falls into.


;
;

Lee's Pharmaceutical Holdings Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,400 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lee's Pharmaceutical Holdings  (HKSE:00950) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Lee's Pharmaceutical Holdings Revenue Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
N/A
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
Executives
Lion River I N.v. 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Leelalertsuphakun Wanee 2101 Beneficial owner
Huang Zuie-chin 2201 Interest of corporation controlled by you
Lue Shuk Ping Vicky 2202 Interest of your spouse
Li Xiaoyi 2101 Beneficial owner
Lee Siu Fong 2101 Beneficial owner
Ubs Group Ag 2201 Interest of corporation controlled by you
Panacea Venture Healthcare Fund Ii, L.p. 2101 Beneficial owner
Panacea Innovation Limited 2201 Interest of corporation controlled by you
Guang Dong Min Ying Tou Zi Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Apta Finance Sa 2201 Interest of corporation controlled by you
Qualister Sa 2101 Beneficial owner
Paponi Claudia 2202 Interest of your spouse

Lee's Pharmaceutical Holdings Headlines

No Headlines